Recruiting

PDAC-PATHWAYS

Sponsor:

Massachusetts General Hospital

Code:

NCT07047807

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PDAC-PATHWAYS

Usual Care

Study Details

Brief summary:

This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Study ID

NCT07047807

Start date

Oct 6, 2025

Status verified date

Jul, 2026

Completion date

Aug, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ageā‰„18 years
  • Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC
  • Able to comprehend and speak English

Exclusion Criteria:

  • Comorbid health condition that would interfere with study participation, as identified by the cancer care team

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: PDAC-PATHWAYS

PDAC-PATHWAYS is an informational and supportive care app for patients initiating neoadjuvant therapy for PDAC.

active comparator: Usual care

Participants randomized to usual care will receive routine treatment with their oncology clinicians.

Interventions

PDAC-PATHWAYS

A digital app for patients initiating neoadjuvant therapy for PDAC

Usual Care

Routine treatment

Primary outcome measure

  • Feasibility: Enrollment rate [ Time Frame: 10 weeks ]
  • Feasibility: intervention completion rate [ Time Frame: 10 weeks ]

Central Contacts and Locations

Central contacts

Kelsey Lau-Min, MD, MSCE

617-724-4000klau-min@mgh.harvard.edu

Locations

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Kelsey Lau-Min, MD, MSCE

857-367-1486klau-min@mgh.harvard.edu

Principal Investigator:

Kelsey Lau-Min, MD, MSCE

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Jul 29, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-07-29.